Trial Profile

A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) in Adults With Recurrent Glioblastoma Multiforme (GBM)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Taniraleucel (Primary) ; Taniraleucel (Primary) ; Cyclophosphamide
Indications Glioblastoma
Focus Adverse reactions; First in man
Acronyms CYNK001GBM01
Sponsors Celularity

Most Recent Events

24 Jan 2022 Status changed from active, no longer recruiting to discontinued due to business decision.
13 Jul 2021 Status changed from recruiting to active, no longer recruiting.
24 Nov 2020 According to a Celularity media release, abstract highlighting the details of this study were presented at the 25th Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO) 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com